Development and evaluation of a composite dosage form containing desmopressin acetate for buccal administration

Desmopressin acetate (DDAVP) is an oligopeptide indicated for the treatment of primary nocturnal enuresis, for example. The poor oral bioavailability of DDAVP accelerated a shift to alternative routes of administration like nasal and oromucosal, whereby nasal administration results in high fluctuati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kottke, Dina, Burckhardt, Bjoern B., Knaab, Tanja C., Breitkreutz, Jörg, Fischer, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220551/
https://www.ncbi.nlm.nih.gov/pubmed/34195604
http://dx.doi.org/10.1016/j.ijpx.2021.100082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220551/
https://www.ncbi.nlm.nih.gov/pubmed/34195604
http://dx.doi.org/10.1016/j.ijpx.2021.100082

Ejemplares similares